Insulet Corporation: Shares Remain Astronomically Expensive

2025-05-28 16:37:45 ET

Summary

• Insulet has shown impressive revenue and profit growth, driven by its leading Omnipod System and expanding global presence.
• Despite strong fundamentals and a large addressable market, Insulet's shares remain significantly overvalued compared to peers.
• Recent financials show continued sales growth, but profitability is complicated by one-off items and high valuation multiples.
• Given the persistent premium valuation, I maintain my "sell" rating, expecting Insulet to underperform the broader market.

Whenever I rate a company a "sell," I don't necessarily expect it to see a decline in share price. Rather, my expectation is that the company will underperform the broader market for the foreseeable future. A good example of this playing out can be seen by looking at Insulet Corporation ( PODD ), a medical device firm known for its Omnipod System, which can deliver a continuous delivery of insulin for those suffering from diabetes as an alternative to the more traditional insulin pump therapies that exist today. Even though this is a fascinating company that has achieved remarkable growth in recent years, I argued back in October of 2022 that it made for a better "sell" than it did a "hold" or a "buy." This was because, quite frankly, shares looked ridiculously expensive....

Read the full article on Seeking Alpha

For further details see: